Form 4: Celularity Director Diamandis Receives Equity Grant

Celularity Inc. director Peter Diamandis was granted 20,385 restricted stock units, aligning his interests with shareholders.

Summary

• Peter Diamandis, a Director of Celularity Inc. (CELU), was granted 20,385 Class A Common Stock restricted stock units (RSUs).
• The transaction date for this acquisition was January 12, 2026.
• These RSUs were granted under the Celularity Inc. 2021 Equity Incentive Plan.
• Each RSU represents a right to receive one share of the Issuer's Class A common stock.
• The RSUs will vest and become exercisable on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, subject to Mr. Diamandis's continuous service with the Issuer.
• Following this transaction, Mr. Diamandis beneficially owns 394,150 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, indicating alignment of interests and a commitment to long-term value creation. It's a routine compensation event, so the positive impact is moderate rather than highly significant.

Positives

• The grant of restricted stock units to a director aligns his financial interests with those of the company's shareholders, promoting long-term value creation.
• Equity incentives are a standard practice for retaining and motivating key management and board members.

Risks

• The vesting of the 20,385 restricted stock units is contingent upon Peter Diamandis's continuous service with Celularity Inc., meaning the shares could be forfeited if his service terminates before the vesting conditions are met.

Future Outlook

The grant of restricted stock units implies an expectation of continued service from Director Peter Diamandis, with the vesting schedule designed to incentivize his ongoing commitment to Celularity Inc.'s performance over the next year or until the next annual stockholder meeting.

Industry Context

Equity grants, such as restricted stock units, are a common and widely accepted form of compensation for directors and executives across the biotechnology and healthcare industries. This practice is designed to align the interests of leadership with those of shareholders, fostering long-term growth and strategic decision-making. Celularity's use of its 2021 Equity Incentive Plan for this grant is consistent with industry standards for attracting and retaining talent.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, similar to grants seen at companies such as Moderna or BioNTech for their board members.
• The vesting schedule, tied to continuous service and a one-year anniversary or next annual meeting, is typical for such grants, aiming to ensure sustained commitment from the director.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns his interests with those of shareholders, potentially leading to more shareholder-friendly decisions and long-term value creation.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The 20,385 restricted stock units granted to Peter Diamandis will vest on the earlier of the one-year anniversary of the grant date (January 12, 2027) or the next annual stockholder meeting, subject to his continuous service.

Key Dates

Keywords

Celularity Inc., CELU, Peter Diamandis, Restricted Stock Units, RSUs, Equity Incentive Plan, Insider Transaction, Form 4, Director Compensation